Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Endoscopic resection of superficial esophageal squamous-cell carcinomas

Endoscopic resection is a safe and effective method of curative treatment in patients with mucosal squamous-cell carcinomas of the esophagus, finds a study in the July issue of the American Journal of Gastroenterology.

News image

fiogf49gjkf04

Endoscopic resection of esophageal squamous-cell neoplasia with curative intent appears to be an alternative treatment to radical surgery when the malignant neoplasia is intraepithelial or limited to the mucosal layer.

This is because the risk for lymph-node metastases is very low, writes Oliver Pech, lead-author of this study.

However, unlike in Japan, experience with endoscopic resection in such cases has been limited in Europe and the United States.

This study is the largest so far in Western countries, and examined patients with early squamous-cell cancer or carcinoma in situ, who were treated using endoscopic resection therapy.

The observational study was conducted between December 1997 and November 2001, when 115 patients with a suspicion of early squamous cancer were referred for local endoscopic therapy.

A total of 39 patients, with mean age 61.4 years, with early esophageal cancer (n = 29) and carcinoma in situ (Cis) (n = 10) were found to fulfill the criteria for local endoscopic therapy. These patients were then treated using endoscopic resection.

The study patients were separated into three groups. Group A composed the 10 Cis patients, group B was made up of 19 patients with mucosal cancer, and the remaining 10 patients formed group C. All patients in group C had submucosal cancer and were either inoperable or had refused surgery.

A total of 94 resections were performed.

Nine of the 10 patients in group A (90%), 19 of the 19 in group B (100%), and 8 of the 10 in group C (80%) achieved a complete response during a mean follow-up period of 29.7 ± 14.3 months.

There were three tumor-related deaths. One was a patient in group B, who was inoperable, while two were group C patients who had refused to undergo surgery.

There were no major complications such as perforation or bleeding requiring blood transfusion recorded during the study, but minor complications were seen in 6 patients (15%).

These comprised 3 patients with minor bleeding after endoscopic resection and 3 with esophageal stenoses, who were successfully treated using injection therapy or dilatation.

90% of patients with carcinoma in situ achieved a complete response following resection
American Journal of Gastroenterology

The researchers calculated 5-year survival as 90% in group A, 89% in group B and 0% in group C.

They conclude that endoscopic resection appears to be an effective and safe method of curative treatment in patients with carcinoma in situ and mucosal squamous-cell carcinomas of the esophagus.

Esophagectomy or chemoradiotherapy, whenever possible, should be the preferred method in patients with submucosal cancer, they advise.

Am J Gastroenterol 2004; 99 (7): 1226 - 1232
12 July 2004

Go to top of page Email this page Email this page to a colleague

 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
c-Myc expression and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us